Choose how you want to use our website:

Cookies help to improve your website experience and provide secure services. Some cookies are essential for security and login functionalities, others enable easier use and convenient support. You can revoke your decision at any time.

Resonandina Holanda BV

Netherlands
Invesdor Alumni
Fixed income
Sustainability
Health
B2B

Profitable impact venture making diagnostics accessible for everyone.

The maximum financing amount of € 1.5 mio. has already been reached. However, you can still invest. In the oversubscription phase, investments up to a total amount of € 1.65 mio. are possible. Priority will be given to investments received first.


Marketing content

Why to invest

Market size: There is a worldwide need for Accessible diagnostics using “capital intensive” medical equipment. The estimate in the addressable market is 100.000+ MRI/CT units by 2030. Resonandina aims at 500+ units with € 150 million annual recurring revenue (“ARR”).

Achievement: Resonandina successfully created a significant market position. Having closed 20+ projects in 10+ countries and has a sound project pipeline

Revenue growth & Profitable: Making the step from start-up to scale-up. With long-term client contracts giving a stable recurring revenue, in 2023 revenue grew 100% and profit 500%. ARR is expected to double again in 2024.

Impact: Funding is used to invest in medical equipment. Increasing the access to diagnostics, supporting SDG 3 “Good Health and Wellbeing”.  

Floriaan vn Bemmelen, CEO Resonandina

"Step into the world of Resonandina, where innovation meets impact! We're pioneers in 'Pay-per-Use' Sustainable Medical lease, transforming healthcare across Latin America and the Caribbean. Last year, over 2,000 crowdfunders and nearly 100 angel investors believed in our vision. Now, with a fresh € 1.5 million funding in 2024, we're expanding our reach. Join us in bringing advanced MRI and PET-CT units to Ecuador and Peru, making a real difference in healthcare accessibility.
Be a catalyst for change. Join Resonandina today!"

Floriaan van Bemmelen, CEO, Resonandina

Investment information

Investing end:
12/06/2024
Type:
Bond
Subordinated:
no
Invested so far:
€1,650,000.00
Price per bond:
€250.00
Min offer:
1 Unit
Interest:
quarterly
Repayment:
quarterly
after 12 Months
Broker:
Oneplanetcrowd International B.V
License:
ECSPR

Overview

Company profile

Resonandina is a profitable, fast-growing medical equipment leasing company. It makes medical devices such as MRI, CT, and Radiotherapy accessible to everyone worldwide through a full-service and pay-per-use leasing model.

Problem: Hospitals often lack money, knowledge, or space for capital intensive medical equipment.

Solution: Resonandina developed an innovative all-inclusive pay-per-use medical lease model that makes diagnostics accessible for everyone.

Capital-intensive equipment becomes affordable for hospitals because a small amount has to be paid each month instead of a large lump sum. The key differentiator of Resonandina is the focus on a ‘simple’ and client oriented “B2B” business model based on “Pay-per-Use” lease with a “all-inclusive” package. The service includes project design, investment, installation, training, full maintenance, and extended life cycle (with upgrades, reuse, and recycling). The hospital has all the medical related responsibilities like patient logistics, quality management, liability and (insurance) invoicing.

We ensure that these hospitals can deploy advanced equipment so that diagnostics become accessible and available to all. This results in healthier people and fewer travel movements.

Resonandina started the services in 2015 in Bolivia with a step-by-step expansion to other Latin American countries. Submarkets are: “doctor owned” medium size hospitals, larger professionally managed hospitals, and Public Healthcare Services.

Having a unique concept of “use it, don’t own it” Resonandina is market leader with focus on the “niche” of high-end medical diagnostic imaging. With a strong partner in GE Healthcare. Fundamental is the Recurring Revenue model with long term (8+ YR) contracts. With 10+ units producing, 10+ in installation, and a pipeline (2024) for 25+ projects there is a great potential.

Resonandina aims at 500+ projects with €150 million ARR on 5 continents. The market size is estimated at 100.000 projects per 2030. Resonandina successfully created a recognized market position, defined the service and operational execution, managed to create ARR and profitability, has proven the concept, prepared footprints in the addressable markets and is ready for the leap ahead.

Company Info 

Company name: Resonandina Holanda BV
Managing Director: Floriaan van Bemmelen
Dennis Korthouwer
Business ID number: 64691772
Founding Year: 2015
Address: Herengracht 449A
1017 BR Amsterdam
The Netherlands
Industry: Healthcare
Number of employees: 12
Locations: Netherlands,
12 subsidiaries in LatAm, USA, Africa & Asia
Website: www.resonandina.com
Social Media:

 

Products and services

Resonandina helps medical facilities not only equip themselves with necessary high-tech machinery but also supports the effective operation and maintenance of these facilities with essential human resources and infrastructure, all adaptable to the needs of specific situations.

Medical Equipment:
Resonandina provides a wide range of hardware equipment such as MRI, CT, Cath Lab, PET/CT, Gamma Cameras, Linear Accelerators, Cyclotrons, and more.

Container Box Type Buildings:
Additionally, we offer "container box type" buildings for specialized circumstances. These are portable, modular buildings designed to house medical equipment or provide extra space for medical services. These are especially useful in situations where permanent construction is not feasible or where mobility and flexibility are required, such as in remote areas or temporary medical camps.

How does it work?

This model is beneficial because it allows hospitals to offer advanced MRI services without bearing the full financial burden of purchasing the equipment. It also helps maintain operational liquidity and adaptability in financial planning. Moreover, the pay-per-use system with volume discounts incentivizes hospitals to maximize the use of the MRI machine, potentially increasing their operational efficiency and profitability. Resonandina offers a “practical and transparent” financial solution, making the service affordable.

Here's a short overview of machine leasing for an MRI-model with Resonandina:

Leasing the MRI Machine

Hospitals lease the MRI machine from Resonandina, avoiding the high initial purchase cost and preserving capital for other uses. Resonandina then ships and sets-up the MRI Machine and arranges training and full maintenance of the MRI in the corresponding hospital.

Pay-Per-Use Payment Structure

Hospitals pay a fixed fee for each MRI scan, with costs decreasing as scan volume increases due to volume discounts. They commit to a minimum number of scans each month, ensuring stable revenue for Resonandina and encouraging efficient machine use.

Billing and Generating Revenue

Hospitals bill patients or their insurers based on agreed local rates. The income from scans covers the MRI lease and operations, potentially generating additional revenue.

Business model

Business model

Business Model

Resonandina employs a unique business model centered on leasing medical equipment under an all inclusive and transparent financial arrangement. Here's an enhanced overview of how their model works:

Financial Model

  • Pay-Per-Use System: Hospitals pay Resonandina a set fee for each diagnostic scan performed, such as an MRI. This aligns the hospital's costs directly with their usage, making the service more affordable and scalable.
  • Volume Discounts: As the volume of scans increases, the cost per scan decreases. This tiered pricing model provides an incentive for hospitals to use the equipment more frequently, which can increase their service to the community and potentially enhance their revenue.
  • Minimum Volume Guarantee: Hospitals agree to a minimum number of scans per month, ensuring a stable and predictable revenue stream for Resonandina and operational efficiency for the hospital.

Revenue and Billing

  • Insurance Billing: Hospitals bill the patients or their insurance companies based on local tariffs and insurance schedules. For instance, if a patient is charged $100 per scan, the hospital pays Resonandina $50 per scan for the first 350 scans, and $45 for subsequent scans. This allows hospitals to maintain profitability while covering their costs.
  • Revenue Potential: The pricing structure and volume guarantees establish a base annual revenue (ARR) that Resonandina can expect, with potential for higher earnings as scan volumes increase.

Contractual and Client Details

  • Long-Term Contracts: The lease agreements typically last between 8 to 15 years, matching the economic lifetime of the equipment.
  • Target Market: Resonandina primarily serves medium-sized, doctor-owned hospitals in regions with over 150,000 inhabitants that lack significant diagnostic services. These hospitals often have limited capital for investment after spending on infrastructure.
  • Larger Hospital Strategy: For bigger, professionally managed hospitals, Resonandina's leasing options offer financial flexibility, allowing these hospitals to invest in other areas while keeping their balance sheets clear of heavy equipment assets.

Partnerships and Operational Support

  • Third-Party Contracts and OEM Partnerships: Resonandina contracts first-class third parties and original equipment manufacturers (OEMs) like GE Healthcare, including distributors such as Global Medical Dominicana and Orimec, as well as companies like JMP Medical and Tekemi. These partnerships are crucial for rigging, shipment, construction, and engineering, ensuring that the equipment is properly installed and maintained.
  • Medical Operational Services: Resonandina offers options for medical operational services, providing radiologic technicians, nurses, and medical reporting staff, usually on a temporary basis in cooperation with partners. This additional support helps hospitals manage increased patient load and complex imaging tasks efficiently.

Operational Strategy

  • Network Establishment: Successfully implementing this model requires Resonandina to maintain a strong network of clients and partners, including hospitals like CEDISA, Hospital Arco Iris, and Kenko Saude, among others. This network helps in ensuring the availability and efficient use of leased equipment across different regions.

Market

Market

Resonandina Revolutionizes Hospital Diagnostic Imaging with Medical Lease Solutions in Rapidly Growing Global Market

Resonandina operates in the Hospital Diagnostic Imagining Services environment. In fact, a typical capital-intensive Equipment Sale market where we developed a Medical Lease solution.

The OECD country average for MRI/CT/PET-CT is 48 per one-million inhabitants. In developing markets, the availability is a fraction thereof.

Estimating the market size: ~115,307 scanners are installed worldwide until 2030. With a lifetime cycle of 15 years, roughly 7,500 units are replaced every year. While markets continue to grow – especially in Latin America (>10% / year) – every year roughly 5,000 units are added to the market. Together this leads to a yearly MRI/CT market opportunity of 12,500 units.

Resonandina aims at 500+ projects with 150 million ARR on 5 continents. The market size is estimated at 100.000 projects per 2030.

The principal competitors are the OEMs like Siemens, Philips and GE Healthcare offering sale including traditional financing with local banks. There is no specific competitor with our full blown USP “pay-per-use” service concept without asset backed guarantees by the client.

Since the Resonandina concept, market footprint, and project pipeline has been reached over the years, the entry-barrier is a complex mix for competition.

Resonandina focus on various countries in Latin America and Caribbean is to diminish local risks and create “first mover advantage” in a “slow moving” dispersed and medical specific “niche market”.

Impact

Resonandina supports SDGs and has aligned policies. Since the start in 2015 and by Dutch RVO supported first project in Bolivia, we have a focus on impact. There is a lack of quantitative research to sustain specific impact of MRI and other Medical Diagnostics on the SDGs. Resonandina is working on practical indicators.

Good Health and Well-Being

SDG 3

Resonandina contributes to Sustainable Development Goal (SDG) 3, which focuses on ensuring healthy lives and promoting well-being for all, by enhancing access to diagnostic services such as MRI scans. By serving approximately 75,000 patients in 2023 and reaching about 2.5 million people in geographically related areas, the company improves early disease detection and treatment, which can lead to stabilized health and increased life expectancy. Additionally, it supports disabled individuals and strengthens healthcare ecosystems by enhancing the skills and capabilities of healthcare professionals. Through these efforts, Resonandina directly supports improved health outcomes and greater healthcare accessibility.

Affordable and Clean Energy

SDG 7

Resonandina contributes to Sustainable Development Goal (SDG) 7, which focuses on affordable and clean energy, by reducing fossil fuel consumption and CO2 emissions. By providing medical diagnostic services closer to patients, the company decreases the need for long-distance travel. This reduction in travel not only conserves energy but also significantly cuts down on CO2 emissions from transportation, supporting cleaner energy use and enhancing environmental sustainability in healthcare delivery.

Responsible Consumption and Production

SDG 12
Resonandina contributes to Sustainable Development Goal (SDG) 12, which promotes responsible consumption and production, by extending the lifespan and promoting the reuse of medical equipment. Through regular maintenance and refurbishment, the company ensures these resources are used efficiently and sustainably, reducing waste and environmental impact while making advanced medical technologies more accessible. This approach supports a more sustainable healthcare sector by fostering efficient resource use and reducing the overall ecological footprint.

Management

  

Floriaan van Bemmelen CEO / Chairman

Floriaan van Bemmelen

CEO / Chairman

Since becoming CEO of Resonandina in 2015, Floriaan van Bemmelen has significantly shaped the company's trajectory. With a background as a general practitioner and director roles in a hospital, an MRI center, and an insurance company, he brings a comprehensive understanding of the healthcare sector. His leadership focuses on enhancing diagnostic technologies and expanding market reach, ensuring that Resonandina remains at the forefront of medical imaging innovation. Floriaan's strategic vision and deep industry knowledge have been pivotal in driving the company’s growth and maintaining its competitive edge in the field.

  

Dennis Korthouwer MBA MSc COO / Board Member

Dennis Korthouwer MBA MSc

COO / Board Member

Dennis Korthouwer has been the COO of Resonandina since 2022, bringing extensive experience from founding, internationally expanding, and financing scaleup ventures. Before joining Resonandina, Mr Korthouwer was CEO of a global gaming venture as well as CEO of a Dutch media company that was later sold to Talpa.

Distribution of company shares

Company shares

QMED BV is a private holding company controlled by founder Floriaan van Bemmelen.

Company structure

You are investing in Resonandina Holanda BV which lends money to its 100% subsidiaries in Peru and Ecuador. These subsidiaries own the equipment and are 100% guarantor. The subsidiaries have to repay this loan to the holding. Both the holding and the subsidiaries can be addressed to repay the Invesdor loan. Besides these two subsidiaries, the Company has 11 other subsidiaries.

company structure

Developments at Resonandina since the last crowdfunding 

In 2023, we successfully raised €4.2 million across three Invesdor (OnePlanetCrowd) funding rounds as well as nearly €3 million from private investors.
Here are the key achievements:

  1. Installations: We initiated and completed installations for 7 projects across several countries: three in the Dominican Republic (one funded by Invesdor), one in Brazil, one in St. Vincent, one in St. Lucia, and one in Colombia (funded by Invesdor).

  2. Revenue: Our revenue surged by nearly 100% to €5 million. This increase was driven by ongoing projects in Brazil, Bolivia, and St Maarten, along with three new projects in the Dominican Republic and a significant project sale.

  3. Profit: Since becoming profitable in 2021, we saw a nearly 500% profit increase in 2023, reaching €275.000. This was achieved while continuing to invest substantially in new projects and expansion efforts.

  4. Impact: We significantly contributed to SDG3 (Good Health and Well-being), enhancing diagnostic access for an estimated 2.5 million people, directly serving 75,000 individuals.

  5. Expansion: We expanded our footprint by signing contracts in new countries and planning future installations. Projects funded by Invesdor set for 2024 include one PET/CT in Peru and three MRIs in Colombia, with an additional PET/CT in Peru and an MRI in Ecuador from the latest funding round.

Looking ahead, we are preparing for potential projects valued at over €25 million, which include expanding the nuclear medicine ecosystem in Peru (adding a Cyclotron, three more PET/CTs, and three Gamma Cameras), five MRIs in the Dominican Republic, three MRIs in Peru, and a comprehensive radiotherapy ecosystem in Colombia, the Caribbean, and Peru.

Use of funds

The funds will be used to finance a MRI in Ecuador and a PET-CT in Peru.

Icon 1

Maximum Scenario

(from €800.000 -  €1,500,000 collected in the financing round)

  • Financing one MRI in Ecuador
  • Financing one PET-CT in Peru

Icon 2

Minimum Scenario

(from €500.000 - €800.000 collected in the financing round)

  • Financing one MRI in Ecuador

Financial figures & growth

Actual and planned figures

Get an insight into Resonandina's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Login Sign up

Documents

Investment related documents

Log in for more information.

Updates

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 28.05.2024: Investor Q&A
 

1. Could you help explain why this project has a 9% interest rate, whereas the recent investment in Resondina was only at 8%? 

The interest rate for investing in Resonandina has increased from 8% to 9% due to recent changes in the broader economic environment, specifically the rise in interest rates within the European Union. The European Central Bank raised rates to control inflation, impacting global financial markets. To remain competitive and attractive to investors in light of these global changes, Resonandina adjusted its interest rate accordingly. This ensures offering competitive returns and maintaining investor interest.

2.Where can I find detailed financial information?

You can find detailed financial information on the project page under the "Financial Figures and Growth" section. Additionally, the KIIS document, available under the "Documents" section, provides comprehensive details. The annual statement is linked under section A(d) on page 2. You can also find a summary of the financial figures from 2021 to 2023 in these documents.

3.Are there reasons why Resonandina is not (yet) expanding its business model to Europe?

Resonandina started in Latin America because hospitals in developing countries often lack the opportunity to buy expensive equipment due to various constraints. Last year the company founded entities in Asia and South Africa while it received some initial requests from there. In the next 1-2 years management believes it will also start operating in developed countries.